Dupilumab
R668-EE-1324
Approved small_molecule active
Quick answer
Dupilumab for Eosinophilic Esophagitis is a Approved program (small_molecule) at Regeneron UK Limited with 4 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Eosinophilic Esophagitis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active